期刊文献+

2型糖尿病患者活化血小板糖基化复合物活性与脂代谢异常的相关性 被引量:1

Glycopropean Complex of Activated Platelet Level and Its Association with Lipid Metabolic Disturbance in Cases of Type 2 Diabetes Mellitus
下载PDF
导出
摘要 探讨 2型糖尿病患者血小板活化与脂代谢异常的关系。将 12 0例 2型糖尿病患者按有无脂代谢异常分为有脂代谢异常组 (n =6 2 )和无脂代谢异常组 (n =5 8) ,并选择 2 5例正常者作对照。应用流式细胞仪分别测定各组的活化血小板糖基化复合物活性 ,比较两组糖尿病患者活化血小板糖基化复合物活性的差异 ,并分析其与甘油三酯、高密度脂蛋白胆固醇及低密度脂蛋白胆固醇水平的相关性。结果发现 ,两组糖尿病患者的活化血小板糖基化复合物活性均明显高于正常对照组 ,且有脂代谢异常的糖尿病组活化血小板糖基化复合物活性高于无脂代谢异常组 ,低密度脂蛋白胆固醇水平与活化血小板糖基化复合物活性显著正相关 (r=0 .6 4,P <0 .0 5 )。结果提示 ,2型糖尿病患者脂代谢异常是导致血小板活化水平增高的重要因素。 Aim To examine the relationship between glycopropean complex of activated platelet (PAC-1) and lipid metabolic disturbance in cases of type 2 diabetes mellitus (DM). Methods One hundred and twenty two patients with DM (type 2) were divided into lipid metabolic disturbance group (62 cases) and normal lipid metabolism group (58 cases). 25 normals were selected as the control. Flow-cytometry was used to detect the PAC-1 level and therefore the deference between the two groups was analysed. The correlation between triglyceride (TG), high density lipoprotein cholesterol (HDLC) and low density lipoprotein cholesterol (LDLC) and PAC-1 was also evaluated. Results The PAC-1 level in type 2 DM cases was higher than that in control subjects. It was also markedly higher in abnormal lipid metabolic cases than that in normal lipid metabolic cases. LDLC correlated positively with PAC-1 (r=0.64, P<0.05). Conclusion Abnormal lipid metabolism is the main factor resulting in a high PAC-1 level.
作者 潘永源 王立
出处 《中国动脉硬化杂志》 CAS CSCD 2003年第5期459-461,共3页 Chinese Journal of Arteriosclerosis
关键词 内科学 血小板活化与脂代谢异常的关系 流式细胞术 2型糖尿病 血小板活化 脂代谢异常 低密度脂蛋白胆固醇 Type 2 Diabetes Mellitus Activated Platelets Abnormal Lipid Metabolism Low Density Lipoprotein Cholesterol Triglyceride High Density Lipoprotein Cholesterol
  • 相关文献

参考文献10

二级参考文献14

  • 1沈捷,陈家伟,刘铨之,黄曼倩,程宝庚,薛婉芬,周大虎.葡萄糖与高脂血清对动脉平滑肌细胞结构的影响[J].中国糖尿病杂志,1994,2(3):139-143. 被引量:12
  • 2叶平.非胰岛素依赖性糖尿病的脂质代谢紊乱与动脉粥样硬化[J].国外医学(老年医学分册),1995,16(3):119-123. 被引量:9
  • 3[1]Jauhiainen M, Ksokinen P, Ehnholm C, et al. Lipoprotien (a) and coronary heart disease risk a nested case-control study of helsinki heart study participants [J]. Atherosclerosis, 1991, 89: 59-63
  • 4[2]Seed M, Hoppicheer F, Reavcey D, et al. Relation of serum lipoprotein (a) concentration and apolipoprotein (a) phenotype to coronary heart disease in patients with family hypercholesterolemia [J]. N Engl J Med, 1990, 322: 1 494-499
  • 5[4]Rainwwter DL, Macclaer JW, Stem MP, et al. Effects of NIDDM on lipoprotein (a) concentration and apolipoprotien (a) size [J]. Diabetes, 1994, 43: 942-946
  • 6[5]Verges BL. Dyslipldaemia in diabetes mellitus. Review of the main lipoprotein abnormalities and their consequences on the development of atherogenesis [J]. Diab Metab, 1999, 25 (Supp l3): 32-40
  • 7[6]Bvscaglia P, Gazzaruso C, GarzanitiA, et al. Lipoprotein (a), apolipoprotein (a) polymorphism, and insulin treatment in type Ⅱ diabetic patients [J]. Diabetes Care, 1995, 18: 1 202-203
  • 8[8]Uterman G, Kraft HG, Menzel HJ, et al. Genetics of the quantitive Lp (a) Lipoprotein trait Ⅰ: relation of Lp (a) glycoprotein phenotypes to Lp (a) lipoprotein concentration in plasma [J]. Hum Genet, 1998, 18: 41-49
  • 9[9]Froguel P. What have we learned thanks to genetics in type Ⅱ diabetes and its complications (editorial) [J]? Nephrologie, 1999, 20 (2): 59-63
  • 10候泽,刘德文,沃兴德,赵革平.脂蛋白脂肪酶单克隆抗体的制备及特性[J].中国动脉硬化杂志,1997,5(2):116-120. 被引量:1

共引文献34

同被引文献2

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部